New Long-Term Treatment for COPD Approved by FDA

New Long-Term Treatment for COPD Approved by FDA

A new long-term treatment for the third largest killer of U.S. citizens – chronic obstructive pulmonary disease (COPD) – was approved today by the U.S. Food and Drug Administration. Striverdi Respimat (olodaterol), an inhalation spray, is for the treatment of patients with COPD, including chronic bronchitis and emphysema that are experiencing airflow obstruction. Striverdi Respimat can be used once daily over a long period of time.

COPD, which is most prevalent among senior citizens, especially those age 65 to 74, is a serious lung disease that makes breathing difficult and worsens over time. Symptoms include wheezing, cough, chest tightness, and shortness of breath. Cigarette smoking is the leading cause of COPD.

Read more by clicking here: http://bit.ly/1uiOvV4